Literature DB >> 23510853

Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.

N Bakrin1, F N Gilly, D Baratti, J M Bereder, F Quenet, G Lorimier, F Mohamed, D Elias, O Glehen.   

Abstract

AIM: Primary peritoneal serous carcinoma (PPSC) is a rare condition, histologically identical to ovarian serous carcinoma and often diagnosed at late stage. There is not any standardized treatment for PPSC. A retrospective multicentric study was performed in French speaking centers to evaluate cytoreduction surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis from different origins. The manuscript's aim was to study the particular population with PPSC.
METHODS: Between September 1997 and July 2007, 36 patients with PPSC from 9 institutions underwent 39 procedures.
RESULTS: Mortality and morbidity rates were 5.6% and 20.6% respectively. The overall survival at 1, 3 and 5 years are respectively 93.6, 71.5 and 57.4%. The median overall survival was not reached. By univariate analysis, the only factor that had prognostic value was PCI (p = 0.03).
CONCLUSIONS: The therapeutic approach combining cytoreductive surgery with HIPEC may achieve long-term survival in patients with PPSC.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23510853     DOI: 10.1016/j.ejso.2013.02.018

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

Review 1.  When is it safe to omit surgery in primary peritoneal cancer with small volume disease?

Authors:  Rachel Pounds; Sean Kehoe
Journal:  Curr Oncol Rep       Date:  2015-08       Impact factor: 5.075

Review 2.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.

Authors:  Tali Shaltiel; Daniel Solomon; Eric R Pletcher; Benjamin J Golas; Deepa R Magge; Umut Sarpel; Daniel M Labow; Noah A Cohen
Journal:  Surg Endosc       Date:  2022-01-26       Impact factor: 3.453

4.  Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India.

Authors:  Naveen Padmanabhan; Barath Raj Kumar; Ansar Pullampara Pookunju; Ayyapan Srinivasan; Vikash Mahajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

5.  Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature.

Authors:  Woo-Sung Yun; Jung-Min Bae
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

6.  Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Thejus T Jayakrishnan; Anthony J Zacharias; Avishkar Sharma; Sam G Pappas; T Clark Gamblin; Kiran K Turaga
Journal:  World J Surg Oncol       Date:  2014-08-21       Impact factor: 2.754

7.  The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Authors:  L Villeneuve; G Passot; O Glehen; S Isaac; F Bibeau; P Rousset; F N Gilly
Journal:  Orphanet J Rare Dis       Date:  2017-02-17       Impact factor: 4.123

Review 8.  Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered.

Authors:  Elie Rassy; Tarek Assi; Stergios Boussios; Joseph Kattan; Julie Smith-Gagen; Nicholas Pavlidis
Journal:  Ann Transl Med       Date:  2020-12

9.  Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial.

Authors:  Yang Liu; Yoshio Endo; Takuji Fujita; Haruaki Ishibashi; Toshihiro Nishioka; Emel Canbay; Yan Li; Shun-Ichiro Ogura; Yutaka Yonemura
Journal:  Ann Surg Oncol       Date:  2014-07-24       Impact factor: 5.344

10.  The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.

Authors:  Hao-Chien Hung; Po-Jung Hsu; Ting-Chang Chang; Hung-Hsueh Chou; Kuan-Gen Huang; Chyong-Huey Lai; Chao-Wei Lee; Ming-Chin Yu; Jeng-Fu You; Yu-Jen Hsu; Jun-Te Hsu; Ting-Jung Wu
Journal:  J Pers Med       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.